Another study published in The Lancet found that DRAK2 was abundantly expressed in breast cancer cells and that knockdown of DRAK2 in breast cancer cells enhanced TGF-β signaling (Wang et al., 2005). This evidence concerns the gene STK17B and breast carcinoma.